A Prospective Comparison of UroVysion FISH and Urine Cytology in Bladder Cancer Detection

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2017 Apr 9

PMID 28388880

Citations 25

Authors

Hugh J Lavery

Boriana Zaharieva

Andrew McFaddin

Nyla Heerema

Kamal S Pohar

Affiliations

Soon will be listed here.

Abstract

Background: UroVysion fluorescence in situ hybridization (uFISH) was reported to have superior sensitivity to urine cytology. However uFISH studies are limited by varying definitions of what is considered a positive result, absence of histopathology and small sample size. The aim of our study was to better determine the performance characteristics of uFISH and urine cytology by overcoming some of the deficiencies of the current literature.

Methods: Intraoperative bladder wash cytology and uFISH were collected prospectively on all patients. Strict definitions for positivity of uFISH and cytology were determined before initiating the study. A re-review of false-negative uFISH specimens was performed to analyze potential sources of error. Sixteen bladder tumors embedded in paraffin were analyzed by uFISH and compared with the result in the urine.

Results: One hundred and twenty-nine specimens were analyzed. Sensitivity was 67% and 69% (p = 0.54); specificity was 72% and 76% (p = 1.0), for uFISH and cytology, respectively. Thirty-two false negative uFISH samples were re-reviewed. Low grade tumors often showed cells with abnormal morphology and patchy DAPI staining but diploid chromosomal counts and a few high grade tumors had tetraploid counts but less than needed to interpret uFISH as positive. uFISH study of the tumors revealed three categories; positive in both tumor and urine (9), negative in both tumor and urine (5) and positive in tumor but negative in urine (2).

Conclusion: In a pathologically-confirmed analysis of bladder washed urine specimens, uFISH does not outperform urine cytology in cancer detection.

Citing Articles

Relapse and Survival in Bladder Cancer Patients Undergoing microRNA-129 and microRNA-145 Assays.

ELfieky M, Abd El Rahman M, Fayed A, Al-Qaim Z, Aldhalmi A, Badr E Asian Pac J Cancer Prev. 2024; 25(6):2113-2121.

PMID: 38918674 PMC: 11382840. DOI: 10.31557/APJCP.2024.25.6.2113.

The Development of Non-Invasive Diagnostic Tools in Bladder Cancer.

Schulz A, Loloi J, Martina L, Sankin A Onco Targets Ther. 2022; 15:497-507.

PMID: 35529887 PMC: 9075009. DOI: 10.2147/OTT.S283891.

Bladder cancer detection in patients with neurogenic bladder: are cystoscopy and cytology effective, and are biomarkers pertinent as future diagnostic tools? A scoping review.

Sbizzera M, Descotes F, Arber T, Neuville P, Ruffion A World J Urol. 2022; 40(8):1897-1913.

PMID: 35119523 DOI: 10.1007/s00345-022-03943-2.

KIF22 promotes bladder cancer progression by activating the expression of CDCA3.

Li K, Li S, Tang S, Zhang M, Ma Z, Wang Q Int J Mol Med. 2021; 48(6).

PMID: 34633053 PMC: 8522959. DOI: 10.3892/ijmm.2021.5044.

Improvement of the Collection, Maintenance, and Analysis of Neoplastic Cells from Urine Specimens with the Use of CytoMatrix.

Minasi S, Bosco D, Moretti B, Giangaspero F, Santoro A, Buttarelli F Methods Protoc. 2021; 4(3).

PMID: 34564311 PMC: 8482097. DOI: 10.3390/mps4030065.

References

Maffezzini M, Campodonico F, Capponi G, Canepa G, Casazza S, Bandelloni R . Prognostic significance of fluorescent in situ hybridisation in the follow-up of non-muscle-invasive bladder cancer. Anticancer Res. 2010; 30(11):4761-5. View

Zellweger T, Benz G, Cathomas G, Mihatsch M, Sulser T, Gasser T . Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer. 2006; 119(7):1660-5. DOI: 10.1002/ijc.21704. View

Hajdinjak T . UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008; 26(6):646-51. DOI: 10.1016/j.urolonc.2007.06.002. View

Bubendorf L, Grilli B, Sauter G, Mihatsch M, Gasser T, Dalquen P . Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol. 2001; 116(1):79-86. DOI: 10.1309/K5P2-4Y8B-7L5A-FAA9. View

Krause F, Rauch A, Schrott K, Engehausen D . Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays?. World J Urol. 2006; 24(4):418-22. DOI: 10.1007/s00345-006-0086-y. View

Sarosdy M, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L . Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol. 2002; 168(5):1950-4. DOI: 10.1016/S0022-5347(05)64270-X. View

Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Zilberstien Y . Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urology. 2005; 66(6):1354-9. DOI: 10.1016/j.urology.2005.07.016. View

Veeramachaneni R, Nordberg M, Shi R, Herrera G, Turbat-Herrera E . Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma. Diagn Cytopathol. 2003; 28(6):301-7. DOI: 10.1002/dc.10291. View

Lotan Y, Shariat S, Schmitz-Drager B, Sanchez-Carbayo M, Jankevicius F, Racioppi M . Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol. 2010; 28(4):441-8. DOI: 10.1016/j.urolonc.2009.11.004. View

10.

Gofrit O, Zorn K, Silvestre J, Shalhav A, Zagaja G, Msezane L . The predictive value of multi-targeted fluorescent in-situ hybridization in patients with history of bladder cancer. Urol Oncol. 2008; 26(3):246-9. DOI: 10.1016/j.urolonc.2007.02.011. View

11.

Panzeri E, Conconi D, Antolini L, Redaelli S, Valsecchi M, Bovo G . Chromosomal aberrations in bladder cancer: fresh versus formalin fixed paraffin embedded tissue and targeted FISH versus wide microarray-based CGH analysis. PLoS One. 2011; 6(9):e24237. PMC: 3164716. DOI: 10.1371/journal.pone.0024237. View

12.

Kipp B, Halling K, Campion M, Wendel A, Karnes R, Zhang J . Assessing the value of reflex fluorescence in situ hybridization testing in the diagnosis of bladder cancer when routine urine cytological examination is equivocal. J Urol. 2008; 179(4):1296-301. DOI: 10.1016/j.juro.2007.11.082. View

13.

Kamat A, Karam J, Grossman H, Kader A, Munsell M, Dinney C . Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int. 2011; 108(7):1119-23. DOI: 10.1111/j.1464-410X.2010.10026.x. View

14.

Varella-Garcia M, Akduman B, Sunpaweravong P, Di Maria M, Crawford E . The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer. Urol Oncol. 2004; 22(1):16-9. DOI: 10.1016/S1078-1439(03)00098-X. View

15.

Stephen Jones J . DNA-based molecular cytology for bladder cancer surveillance. Urology. 2006; 67(3 Suppl 1):35-45. DOI: 10.1016/j.urology.2006.01.039. View

16.

Skacel M, Fahmy M, Brainard J, Pettay J, Biscotti C, Liou L . Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 2003; 169(6):2101-5. DOI: 10.1097/01.ju.0000066842.45464.cc. View

17.

Bergman J, Reznichek R, Rajfer J . Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings. BJU Int. 2007; 101(1):26-9. DOI: 10.1111/j.1464-410X.2007.07183.x. View

18.

Youssef R, Schlomer B, Ho R, Sagalowsky A, Ashfaq R, Lotan Y . Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology. Urol Oncol. 2010; 30(3):273-7. DOI: 10.1016/j.urolonc.2010.02.012. View

19.

Dimashkieh H, Wolff D, Smith T, Houser P, Nietert P, Yang J . Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. 2013; 121(10):591-7. PMC: 3800248. DOI: 10.1002/cncy.21327. View

20.

Yoder B, Skacel M, Hedgepeth R, Babineau D, Ulchaker J, Liou L . Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol. 2007; 127(2):295-301. DOI: 10.1309/ADJL7E810U1H42BJ. View